Inactive Instrument

Press Releases Aerie Pharmaceuticals, Inc.

Equities

AERI

US00771V1089

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

Alcon Completes Acquisition of Aerie Pharmaceuticals, Inc., Strengthening Company's Ophthalmic Pharmaceutical Business	22-11-22	AQ
AERIE PHARMACEUTICALS INC : Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements an (form 8-K)	22-11-21	AQ
AERIE PHARMACEUTICALS INC : Submission of Matters to a Vote of Security Holders (form 8-K)	22-11-18	AQ
Aerie Pharmaceuticals : Merger Agreement - Form 8-K	22-11-07	PU
AERIE PHARMACEUTICALS INC : Other Events (form 8-K)	22-11-07	AQ
AERIE PHARMACEUTICALS INC Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	22-11-04	AQ
Aerie: Q3 Earnings Snapshot	22-11-03	AQ
AERIE PHARMACEUTICALS INC : Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	22-11-03	AQ
Aerie Pharmaceuticals Reports Third Quarter 2022 Financial Results	22-11-03	BU
Co-Chairs from Aerie Pharmaceuticals & Santen Inc. USA Invite Industry Experts to Join Ophthalmic Drugs	22-10-28	AQ
AERIE PHARMACEUTICALS - INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Aerie Pharmaceuticals, Inc. - AERI	22-10-14	BU
Aerie Pharmaceuticals to Host Key Opinion Leader Event on Dry Eye Disease, Current Landscape, Unmet Needs, and Emerging Treatment Options	22-09-14	AQ
AERIE PHARMACEUTICALS INC : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	22-09-13	AQ
Aerie Pharmaceuticals to Host Key Opinion Leader Event on Dry Eye Disease: Current Landscape, Unmet Needs, and Emerging Treatment Options	22-09-13	BU
AERIE PHARMACEUTICALS - INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Aerie Pharmaceuticals, Inc. - AERI	22-08-24	BU
AERIE PHARMACEUTICALS INC : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)	22-08-23	AQ
AERIE PHARMACEUTICALS INC : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	22-08-23	AQ
Aerie Pharmaceuticals Announces New Employee Inducement Grant	22-08-15	BU
Aerie Pharmaceuticals : Reports Second Quarter 2022 Financial Results and Provides Business Update - Form 8-K	22-08-05	PU
AERIE PHARMACEUTICALS INC Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	22-08-05	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Aerie Pharmaceuticals, Inc.

Equities

AERI

US00771V1089

Press Releases

Filters